National Mental Illness Awareness Week Addresses Stigmas – Drug for nerve pain boosts high for opioid abusers.

1999_GraphicImage_061815-piAabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

National Mental Illness Awareness Week Addresses Stigmas – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

It is likely that everyone knows someone—either a friend, family member, or coworker—who is struggling with a mental illness. Despite the fact that millions of Americans live mental illnesses each year, patients are often misunderstood and stigmatized.

Each year the National Alliance on Mental Illness (NAMI) brings awareness to mental illnesses during the first full week of October, observing it as National Mental Illness Awareness Week. This year, the observation is taking place from October 7-13. All this week, NAMI is striving to educate the public on mental illness, fight the stigma associated with it, and provide support for those struggling, according to a statement from the organization.

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

FDA Approves Second Drug Treatment for Polyneuropathy – APhA submits compounding comments to FDA.

2507_GraphicImage_062315-piAlabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

FDA Approves Second Drug Treatment for Polyneuropathy – APhA submits compounding comments to FDA. – (866) 348-2889.

The FDA has approved inotersen (Tegsedi, Akcea Therapeutics), an antisense oligonucleotide (ASO) that inhibits the production of the transthyretin (TTR) protein (amyloid), for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults.1,2 This is the second FDA approved drug for hATTR, following patisiran (Onpattro), which was approved August 10.1

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

PQA Applauds Congressional Passage of Opioid Legislation – Drug for nerve pain boosts high for opioid abusers.

2501_GraphicImage_061915-piAabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

PQA Applauds Congressional Passage of Opioid Legislation – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

The Pharmacy Quality Alliance (PQA) has released a statement praising the bipartisan efforts of Congress in passing the SUPPORT for Patients and Communities Act (HR 6), comprehensive legislation aimed at combating the growing opioid abuse crisis.1

HR 6—which was passed in the Senate on Wednesday and in the House of Representatives last week—instructs the Secretary of Health and Human Services to establish a technical expert panel to review quality measures regarding opioids and opioid use disorders. Once established, the panel will evaluate current and in-development quality measures, identify gaps in these measures, and make recommendations.1,2

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

Study: In Utero Antiretroviral Exposure Possibly Linked to Neurologic Outcomes – APhA submits compounding comments to FDA.

1987_GraphicImage_060915_GrAlabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Study: In Utero Antiretroviral Exposure Possibly Linked to Neurologic Outcomes – APhA submits compounding comments to FDA. – (866) 348-2889.

Efavirenz exposure (EVF) in utero is being linked to higher risk of neurologic abnormalities in infants and children. The association was made through a study by the Pediatric HIV/AIDS Cohort Study (PHACS) network that analyzed antiretroviral (ARV) medication exposure and possible adverse neurologic outcomes.1

ARV therapy for pregnant women with HIV has dramatically decreased preinatal transmission of HIV, according to researchers, but concerns regarding adverse neurologic outcomes from possible mitochondrial dysfunction or other mechanisms in children exposed to in utero ARV medications remain. The Surveillance Monitoring for ART Toxicities (SMARTT) study’s primary outcome of interest was a “neurologic case,” as determined by clinical review blinded to ARV exposure.1 Results of the study were presented Thursday at the ID Week conference in San Francisco.

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

Recommending Prenatal Vitamins: A Pharmacist’s Guide – Drug for nerve pain boosts high for opioid abusers.

1Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Recommending Prenatal Vitamins: A Pharmacist’s Guide – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Vitamin and mineral supplementation is often recommended for proper fetal development, during preconception and pregnancy. In addition to a healthy diet, incorporating a vitamin and mineral supplement can aid the mother in obtaining appropriate nutrients. Each component of a prenatal multivitamin conveys a specific benefit to the mother and developing baby. A multivitamin taken during pregnancy has been shown to double the chance of giving birth beyond 41 weeks.1

This guide reviews supplementation recommendations for pregnant women without concomitant disease states and without concurrent medications and can be used to aid the pharmacist in recommending and evaluating a prenatal vitamin for a patient.

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

CDC: Workplace Initiatives Lead to Increased Flu Vaccination – APhA submits compounding comments to FDA.

1594_GraphicImage_051115Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

CDC: Workplace Initiatives Lead to Increased Flu Vaccination – APhA submits compounding comments to FDA. – (866) 348-2889.

Officials with the FDA have approved sarecycline (Seysara, Paratek and Almirall) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 9 years and older.1-2 The drug is expected to be available in the United States market in January.1

Efficacy of Seysara was assessed in a pair of 12-week, multicenter, randomized, double-blind, placebo-controlled studies with 2,002 participants aged 9 years and older.1 The 2 co-primary efficacy endpoints were the percentage of subjects with Investigator’s Global Assessment success and absolute reduction from baseline in inflammatory lesion counts at Week 12.1-2 The efficacy of Seysara beyond 12 weeks and its safety beyond 12 months have not been determined.2

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

Survey: Vaccination in Pregnant Women Increases with Access and Education from Providers – Drug for nerve pain boosts high for opioid abusers.

3Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Survey: Vaccination in Pregnant Women Increases with Access and Education from Providers – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

The CDC’s Advisory Committee on Immunization Practices recommends that all women who are or may become pregnant during flu season receive an influenza vaccine, and all pregnant women receive a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.

The CDC analyzed survey data to assess influenza and Tdap vaccination among pregnant women during the 2017-2018 flu season and determined that health care providers can increase vaccination by offering vaccines or referring patients to someone who can provide them, and by educating patients on the safety, efficacy, and necessity of vaccines during pregnancy.

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

CDC: Workplace Initiatives Lead to Increased Flu Vaccination – APhA submits compounding comments to FDA.

4Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

CDC: Workplace Initiatives Lead to Increased Flu Vaccination – APhA submits compounding comments to FDA. – (866) 348-2889.

All health care professionals should receive an annual influenza vaccine to both prevent the spread of illness among their colleagues and patients and reduce the amount of sick days taken by health care personnel, according to the Advisory Committee on Immunization Practices (ACIP).

A recent survey concluded that strategies to increase workplace immunization, such as requiring vaccination or promoting free onsite vaccines, lead to increased vaccination rates, according to the CDC Morbidity and Mortality Weekly Report.

The CDC surveyed 2,265 health care professionals to determine how many were vaccinated during the 2017-2018 flu season and concluded that 74.8% had received a flu vaccine. This data was consistent with data collected during the past 4 flu seasons, according to the CDC.

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

Methocarbamol Tablets for Treating Musculoskeletal Conditions are Recalled – Drug for nerve pain boosts high for opioid abusers.

5Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Methocarbamol Tablets for Treating Musculoskeletal Conditions are Recalled – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Two lots of Robaxin® (methocarbamol tablets, USP) 750mg Tablets 100 Count Bottle pack are being voluntarily recalled by Endo Pharmaceuticals Inc., due to incorrent dosing information on the label.

Robaxin® 750mg Tablets contain the active ingredient methocarbamol and are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions, as an adjunct therapy to rest, physical therapy and other measures.

The labeling error misstates the daily dose as “two to four tablets four times daily” rather than the correct dosage of “two tablets three times daily,” according to the FDA. The recalled products include Robaxin® 750mg, 100 Count Bottle pack, Lot 216702P1, Expiration Date: September 2020; and Lot 220409P1, Expiration Date: January 2021. No other lots of Robaxin® are affected by this market action.

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

FDA Approves New Epinephrine Product for Children – APhA submits compounding comments to FDA.

7Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

FDA Approves New Epinephrine Product for Children – APhA submits compounding comments to FDA. – (866) 348-2889.

Officials with the FDA have approved another new epinephrine auto-injector. Admais’ 0.15mg Symjepi is indicated for the emergency treatment of allergic reactions, including anaphylaxis, in children.1,2

The latest announcement joins a previous approval from the agency for Admais’ 0.3 mg epinephrine auto-injector.1 In addition, the FDA approved in August the nation’s first truly generic epinephrine auto-injector, in 0.15 mg and 0.3 mg doses, by Teva Pharmaceuticals.3 These products are all expected to become available to the pharmacy market in the near future.1,3

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off